Objective: To report the results of treatment with infliximab in patients with refractory juvenile idiopathic arthritis (JIA).

Patients and methods: A prospective study of four children with refractory JIA was carried out. Infliximab (100 mg) was administered in weeks 0, 2 and 6. Subsequently, the drug was administered every 8 weeks. The following parameters were assessed at the beginning and at the end of the follow-up period: number of joints with active arthritis, number of joints with a limited range of motion, physician overall assessment of disease activity, parent assessment of the child’s overall well-being, pain assessment scores, and erythrocyte sedimentation rate. Improvement was rated according to the definition of the American College of Rheumatology (ACR 30). Paired sample tests were used for statistical analysis.

Results: Three girls and one boy aged between 10 and 16 years old with a history of JIA ranging from 1 to 9 years were included. The patients received infliximab for a period of 11 to 33 months (average 22 months). There was a significant decrease in the number of swollen joints (p < 0.05), joints with a limited range of movement (p < 0.04), pain score assessment (p < 0.005), physician overall assessment (p = 0.002), maternal evaluation (p < 0.001), the patient’s own evaluation (p < 0.001), and duration of morning stiffness (p < 0.001). Both steroids and methotrexate dosages were reduced and no adverse effects or infections were registered.

Conclusions: Infliximab improved joint inflammatory indexes and clinical assessments. This improvement increased the quality of life of the patients and their families, suggesting that the use of biological therapy is a good option in refractory JIA.

Key words: Juvenile idiopathic arthritis. Infliximab. Juvenile rheumatoid arthritis.

INTRODUCTION

Juvenile idiopathic arthritis (JIA) is the most common rheumatologic disease in the pediatric population. According to a national study, the estimated incidence in Chile is 5.6 cases per 100,000 children under fifteen years of age. Presentation, clinical course, laboratory parameters, and response to therapy may vary widely. It has been necessary to classify the disease in subgroups in order to identify those patients whose prognosis and response to therapy might be different.
Most patients respond to conventional management with non-steroidal anti-inflammatory drugs (NSAIDs) and disease-modifying anti-rheumatic drugs (DMARDs), especially if administered early during the course of the illness. These agents have both, improved disease prognosis and allowed steroids doses to be reduced, consequently reducing their associated side effects. However, a significant number of patients in the polyarticular JIA subgroups or systemic JIA with polyarticular involvement experience severe and aggressive disease resulting in erosive arthritis, joint destruction, functional disability, growth retardation and unresponsiveness to treatment, even when begun early. The persistent disease activity compounded by the cumulative side effects of long term medication has a significant impact in emotional and psychological development, quality of life and family dynamics. For these refractory groups, the use of biological therapies such as tumor necrosis factor alpha (TNFα) antagonists has been suggested. These biological agents have shown therapeutic efficacy in Rheumatoid Arthritis (RA). They modify its course and prognosis by blocking the inflammatory activity of TNFα. This produces a down regulation of the inflammatory response resulting in decrease proliferation of synoviocytes, collagenase production, cell-adhesion molecules expression, bone resorption and cartilage destruction.

The purpose of this study is to report our clinical findings on the use of infliximab, a monoclonal antibody that neutralizes the pro-inflammatory action of tumor necrosis factor alfa (TNFα), in pediatric patients suffering from JIA refractory to conventional therapies.

PATIENTS AND METHOD

Four children with the diagnosis of JIA, followed up at the Immunology Unit of the Exequiel Gonzalez Cortes Hospital were included: two girls had systemic JIA with polyarticular involvement; one had seronegative polyarticular JIA and one boy had JIA associated to enthesitis.

Infliximab (Remicade®, Schering Plough, USA) was administered through a continuous infusion pump at dosages ranging from 2.5 to 2.9 mg/Kg/dose (median 2.75), at weeks 0, 2 and 6. Subsequently, they received the drug every 8 to 10 weeks. During the first year, patients were admitted to the hospital for treatment for a period of 24 hours. They were kept in isolation and monitored hourly. Later on, because no adverse reactions developed, hospital stay was reduced to six hours.

The following parameters were evaluated at week 0 and at the end of the follow up period: number of joints with active arthritis, number of joints with limited range of motion, physician global evaluation of disease activity and parent assessment of child’s overall well-being (rating 10 for maximum disease activity and 0 for no disease activity). Likewise, pain rating by the patient was done using a visual analogue scale. Serum measurements of acute phase reactants were obtained. The definition of improvement of RA by the American College of Rheumatology (ACR 30) was applied. This is based in the overall assessment of decreased disease activity done by a physician; overall assessment of disease activity according to the patient or his/her mother, functional ability, number of joints with active arthritis, number of joints with limited range of movement and ESR.

Improvement of at least 30 % from baseline from the beginning of the new therapy in 3 of the 6 variables included and not more than one variable worsening by more than 30 % was considered significant. In the overall assessment, a maternal evaluation was included because the patients were children. Furthermore, it was considered of clinical interest to assess morning stiffness in minutes and reduction or suspension of steroid and methotrexate.

The t-test for paired samples was employed to compare the changes in JIA parameter for each patient between entry and end of treatment with infliximab. Results are expressed as mean and standard deviation; a value of p < 0.05 was considered statistically significant. The protocol had the approval from the local Ethics Committee and full informed and signed consent was obtained from parents.

RESULTS

Four patients, three girls and one boy, ranging from 10 to 16 years of age, with 1 to 9 years of disease history, were included in the study. They had been taking NSAIDs, oral steroids (0.2 to 0.3 mg/kg/day prednisone equivalent), and methotrexate (10.8 to 12.7 mg/m²/week), subcutaneously. The patient with JIA associated to enthesitis was also taking mesalazine (53Norambuena R X et al.—ANTI-TNF IN JUVENILE IDIOPATHIC ARTHRITIS 35(2):52-6)

Allergic et Immunopathol 2007;35(2):52-6
swollen joints, the number of joints with limited range of motion, morning stiffness in minutes, and pain assessment on the Visual Analogue Scale at the beginning and at the end of the follow-up period. All variables showed a statistically significant decrease by the end of the study period.

Table I
Clinical Assessment Parameters both at the week 0 and at the end of follow up

<table>
<thead>
<tr>
<th>Case</th>
<th>N.º swollen joints</th>
<th>N.º joints with limited range of motion</th>
<th>VAS pain (0-10)</th>
<th>Morning Stiffness (minutes)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Week 0</td>
<td>End</td>
<td>Week 0</td>
<td>End</td>
</tr>
<tr>
<td>1</td>
<td>22</td>
<td>2</td>
<td>19</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>14</td>
<td>2</td>
<td>17</td>
<td>2</td>
</tr>
<tr>
<td>3</td>
<td>20</td>
<td>2</td>
<td>18</td>
<td>4</td>
</tr>
<tr>
<td>4</td>
<td>2 + 4 E</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>p</td>
<td>0.049</td>
<td></td>
<td>0.038</td>
<td></td>
</tr>
</tbody>
</table>

VAS, Visual Analogue Scale; 4 E, four points for enthesitis.

Table II
Overall assessment and ESR both at the week 0 and at the end of follow up.

<table>
<thead>
<tr>
<th>Case</th>
<th>Physician overall assessment (0-10)</th>
<th>Patient overall assessment (0-10)</th>
<th>Mother overall assessment (0-10)</th>
<th>ESR (mm/hr)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Week 0</td>
<td>End</td>
<td>Week 0</td>
<td>End</td>
</tr>
<tr>
<td>1</td>
<td>10</td>
<td>2</td>
<td>10</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>9</td>
<td>1</td>
<td>10</td>
<td>2</td>
</tr>
<tr>
<td>3</td>
<td>9</td>
<td>2</td>
<td>10</td>
<td>3</td>
</tr>
<tr>
<td>4</td>
<td>6</td>
<td>1</td>
<td>9</td>
<td>2</td>
</tr>
<tr>
<td>Average</td>
<td>7.5,3</td>
<td>23,5</td>
<td>0,002</td>
<td>0,00</td>
</tr>
</tbody>
</table>

Table III
Assessment of change in selected variables

<table>
<thead>
<tr>
<th>Variable*</th>
<th>Average</th>
<th>SD</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>N.º of swollen joints</td>
<td>13</td>
<td>8.08</td>
<td>0.049</td>
</tr>
<tr>
<td>N.º of joints with limited range of motion</td>
<td>12</td>
<td>6.78</td>
<td>0.038</td>
</tr>
<tr>
<td>Physician Assessment</td>
<td>7</td>
<td>1.83</td>
<td>0.005</td>
</tr>
<tr>
<td>Patient Assessment</td>
<td>7.5</td>
<td>0.58</td>
<td>0.00</td>
</tr>
<tr>
<td>Mother Assessment</td>
<td>8.3</td>
<td>0.5</td>
<td>0.00</td>
</tr>
<tr>
<td>ESR</td>
<td>49.5</td>
<td>40.7</td>
<td>0.093</td>
</tr>
</tbody>
</table>

*Week 0-end.
SD, standard deviation; VAS, visual analogue scale; ESR, erithrocyte sedimentation rate.

Neither adverse reactions nor severe infections were seen in this series. Parents also agreed that the quality of family life had improved.
DISCUSSION

Based on standardized clinical and laboratory parameters of disease activity we have shown that this group of pediatric patients suffering from JIA refractory to conventional therapies had good response to infliximab treatment and a consistent improvement of their quality of life.

One patient (case 1) began therapy at 16 years of age, after nine years of clinical disease activity and evidence of radiological progression. The disease course showed erosive polyarticular involvement, more predominant in the lower extremities. As soon as clinical and laboratory inactivity was shown, hip and knee arthroplasties were planned. We emphasized the improvement of functional ability from Steinbrocker grade IV to II for RA.

The case 2 was a 13-year-old patient with a five-year course of systemic JIA involving axial and several peripheral joints. She had a history of two macrophage activation events which required intravenous immunoglobulin and high doses steroid. All this lead to secondary Cushing syndrome and stunted growth. After 18 months of treatment with infliximab, a significant reduction of inflammatory articular scores and steroid dose was obtained with no evidence of macrophage activation.

The third patient (case 3) was a girl with systemic onset of JIA at the age of 9 with a rapidly progressive polyarticular disease and grade III functional ability at the start of infliximab therapy. Treatment began one year after the start of the disease and after 26 months of treatment, the patient has improved to grade I functional ability and was on low doses of oral steroids without methotrexate.

Finally, a boy (case 4) diagnosed with active Ulcerative Colitis and Bronchial Asthma, refractory to conventional high-dose treatments. He had active and progressive JIA with functional limitations, morning stiffness and ankle arthritis associated to enthesitis which restricted both, daily and school activities. After eight months of infliximab administration, methotrexate was successfully discontinued; no reactivation of Bronchial Asthma was seen, therapy for Ulcerative Colitis remained unaltered and prednisone doses were reduced. Four months after discontinuing infliximab treatment, the patient is still rheumatologically inactive.

Better knowledge of RA pathogenesis, especially JIA, in addition to the concept of immune-mediated diseases, have brought about changes in the therapeutic schemes. TNFα is a fundamental cytokine in joint inflammatory response; in fact, high TNFα concentrations are found in the synovial fluid of these patients. TNFα is produced by cells located at the cartilage-pannus junction and may affect chondrocyte metabolism through cartilage destruction. The role of cytokines, especially TNFα, has been extensively studied. It has been shown that interleukin 1 (IL-1), IL-6 and TNFα play a role in inflammatory activity and stimulate both synovial cell proliferation by inducing production of collagenase and bone resorption. Moreover, it triggers the release of adhesion molecules. TNFα binds to one of two cell membrane receptor sites (p55/p60 or p75/p80), causing joint inflammation, cartilage destruction and various other clinical manifestations of the disease.

Two pharmacological mechanisms have been used to inhibit TNFα activity: one works through the development of anti-TNFα monoclonal antibodies like infliximab (a macromolecule composed of human IgG and a fraction of murine origin that constitutes the union site of TNFα and adalimumab (Humira®, a human monoclonal antibody which is similar both in composition and pharmacological action). The other mechanism used to inactivate TNFα is to block the soluble receptor, as the case of etanercept (Enbrel®), in this case, receptor molecules separated from the cell surface act as competitive TNFα inhibitors. The availability of TNFα antagonists for clinical use has modified the therapeutic schemes even in early stages of RA, as reported with the use of infliximab combined with methotrexate, which inhibited the progression of structural damage during a two-year treatment period, pointing to a potential long-term benefit by preventing the progression of radiological joint damage.

In RA, improvement has been shown in therapeutic response indexes based on ACR criteria. The use of biological action drugs combined with methotrexate has accomplished better therapeutic responses and improvements in immunological tolerance than the administration of the anti-TNF therapy alone. The ATTRACT study (Anti-TNF Therapy in Rheumatoid Arthritis) showed that patients with active RA who received infliximab and methotrexate had augmented clinical and radiological benefits at 30, 54 and 102 weeks.

Collaborative studies in JIA using etanercept have been conducted with promising results. An open multicentric collaborative study assessed etanercept safety and efficacy in children older than four years of age with active polyarticular-type disease and small tolerance or inadequately responsiveness to methotrexate. Responders were included in a double-blind study where either placebo or etanercept were given for a period of four months or until relapse was seen. The responders were defined as those individuals showing at least 30 % improvement in three out of six indicators of disease activity. They concluded that
etanercept caused significant disease improvement with good drug tolerance. In another prospective, non-randomised, open study of children over 3 years of age with refractory polyarticular JIA, infliximab was given to 14 patients and etanercept was administered to 10 patients. DMARDs were also used. There was significant improvement in both groups of patients, allowing for a reduction or discontinuation of DMARDs in selected cases. We had a similar experience with our patients. During our follow-up period, with infliximab administered at regular intervals for a minimum of eleven months, patients showed clear improvement according to current ACR criteria, better than ACR 30, with no adverse effects or infections. At present, they are rheumatologically inactive and autonomous in their daily life.

From this experience, with the use of infliximab in four pediatric patients with refractory JIA, we found a significant improvement in clinically status and quality of life. Furthermore, no adverse effects were seen in our patients. We believe that our results add information on the effectiveness and safety of Infliximab as previously reported, although multicenter clinical trials are still needed. We expect that in the near future, the administration of biological therapy could be indicated earlier during the course of the disease, mainly in rapidly progressive cases and also in refractory JIA.

ACKNOWLEDGMENTS

We thank to Dr. Alejandra Aird her technical assistance.

REFERENCES